Orchid Cellmark Reports First Quarter 2008 Financi...(results this year and for future growth ...),Health

Date:5/8/2008

results this year and for future growth in the coming years and the belief the company is on the right path to achieve sustainable profitability. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, the risk that we are not able to regain or replace services that we previously provided to several police forces in the U.K. under an arrangement with LGC, the risk that the amount of revenue resulting from the North West/South West and Wales regional tender in the U.K. is not significant, Orchid Cellmark's ability to timely and successfully integrate ReliaGene's business, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as ma
'/>"/>

SOURCE Orchid Cellmark Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
2. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
3. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
4. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
5. Orchid Cellmark Reports Third Quarter 2007 Financial Results
6. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
7. Micromet, Inc. Reports First Quarter 2008 Financial Results
8. Labopharm Reports Results for First Quarter Fiscal 2008
9. Caliper Life Sciences Reports First Quarter 2008 Results
10. US Oncology Reports First Quarter 2008 Results
11. The Ensign Group, Inc. Reports First Quarter 2008 Earnings